353 related articles for article (PubMed ID: 28533225)
1. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
[No Abstract] [Full Text] [Related]
2. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.
Bharadwaj U; Eckols TK; Xu X; Kasembeli MM; Chen Y; Adachi M; Song Y; Mo Q; Lai SY; Tweardy DJ
Oncotarget; 2016 May; 7(18):26307-30. PubMed ID: 27027445
[TBL] [Abstract][Full Text] [Related]
3. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
Zuo M; Li C; Lin J; Javle M
Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
[TBL] [Abstract][Full Text] [Related]
4. C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma.
Di JX; Zhang HY
Anticancer Drugs; 2019 Sep; 30(8):846-853. PubMed ID: 30870229
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet.
Miura K; Ohnishi H; Morimoto N; Minami S; Ishioka M; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Isoda N; Yamamoto H
Cancer Sci; 2019 Feb; 110(2):771-783. PubMed ID: 30520543
[TBL] [Abstract][Full Text] [Related]
6. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
8. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
Teng KY; Han J; Zhang X; Hsu SH; He S; Wani NA; Barajas JM; Snyder LA; Frankel WL; Caligiuri MA; Jacob ST; Yu J; Ghoshal K
Mol Cancer Ther; 2017 Feb; 16(2):312-322. PubMed ID: 27980102
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
10. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model.
Zhao Y; Wang J; Liu WN; Fong SY; Shuen TWH; Liu M; Harden S; Tan SY; Cheng JY; Tan WWS; Chan JKY; Chee CE; Lee GH; Toh HC; Lim SG; Wan Y; Chen Q
Hepatology; 2021 Sep; 74(3):1395-1410. PubMed ID: 33738839
[TBL] [Abstract][Full Text] [Related]
11. Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway.
Wu L; Li J; Liu T; Li S; Feng J; Yu Q; Zhang J; Chen J; Zhou Y; Ji J; Chen K; Mao Y; Wang F; Dai W; Fan X; Wu J; Guo C
Cancer Med; 2019 Aug; 8(10):4806-4820. PubMed ID: 31273958
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma.
Liu T; Ma H; Shi W; Duan J; Wang Y; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
Int J Oncol; 2017 Aug; 51(2):555-562. PubMed ID: 28714512
[TBL] [Abstract][Full Text] [Related]
13. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.
Liao J; Xu T; Zheng JX; Lin JM; Cai QY; Yu DB; Peng J
Int J Mol Med; 2013 Jul; 32(1):79-84. PubMed ID: 23613111
[TBL] [Abstract][Full Text] [Related]
14. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling.
Tan ZB; Fan HJ; Wu YT; Xie LP; Bi YM; Xu HL; Chen HM; Li J; Liu B; Zhou YC
J Ethnopharmacol; 2019 Mar; 232():62-72. PubMed ID: 30553869
[TBL] [Abstract][Full Text] [Related]
15. Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas.
Kakehashi A; Stefanov VE; Ishii N; Okuno T; Fujii H; Kawai K; Kawada N; Wanibuchi H
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218651
[TBL] [Abstract][Full Text] [Related]
16. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
17. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T
Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470
[TBL] [Abstract][Full Text] [Related]
18. Notch Inhibitor PF-03084014 Inhibits Hepatocellular Carcinoma Growth and Metastasis via Suppression of Cancer Stemness due to Reduced Activation of Notch1-Stat3.
Wu CX; Xu A; Zhang CC; Olson P; Chen L; Lee TK; Cheung TT; Lo CM; Wang XQ
Mol Cancer Ther; 2017 Aug; 16(8):1531-1543. PubMed ID: 28522590
[TBL] [Abstract][Full Text] [Related]
19. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
20. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
